CC-1, PSMAxCD3

Phase 1Small molecule

UUniversity Hospital Tuebingen

CC-1, PSMAxCD3 is one of 47 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Prostate CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

1 3

Lupron

Zometa

Ritalin

Plaquenil

Alnylam Pharmaceuticals

Jevtana

Lynparza

Balversa

Estrace

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Carcinoma1 trial

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT04104607·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CC-1, PSMAxCD3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-1, PSMAxCD3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-1, PSMAxCD3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

CC-1, PSMAxCD3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News